NASDAQ:NCNA - NuCana Stock Price, News & Analysis

-1.65 (-19.19 %)
(As of 08/16/2019 04:00 PM ET)
Today's Range
Now: $6.95
50-Day Range
MA: $9.38
52-Week Range
Now: $6.95
Volume50,900 shs
Average Volume12,209 shs
Market Capitalization$224.00 million
P/E RatioN/A
Dividend YieldN/A
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. It is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; Phase Ib clinical trials for the treatment of recurrent ovarian cancer; Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary cancer; and Phase III clinical trials for the treatment of pancreatic cancer. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:NCNA



Sales & Book Value

Annual SalesN/A
Book Value$3.42 per share


Net Income$-18,470,000.00


Market Cap$224.00 million
Next Earnings Date8/27/2019 (Estimated)
OptionableNot Optionable

Receive NCNA News and Ratings via Email

Sign-up to receive the latest news and ratings for NCNA and its competitors with MarketBeat's FREE daily newsletter.

NuCana (NASDAQ:NCNA) Frequently Asked Questions

What is NuCana's stock symbol?

NuCana trades on the NASDAQ under the ticker symbol "NCNA."

When is NuCana's next earnings date?

NuCana is scheduled to release their next quarterly earnings announcement on Tuesday, August 27th 2019. View Earnings Estimates for NuCana.

What price target have analysts set for NCNA?

3 brokers have issued 12-month price objectives for NuCana's shares. Their predictions range from $36.00 to $36.00. On average, they anticipate NuCana's stock price to reach $36.00 in the next twelve months. This suggests a possible upside of 418.0% from the stock's current price. View Analyst Price Targets for NuCana.

What is the consensus analysts' recommendation for NuCana?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NuCana in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NuCana.

Has NuCana been receiving favorable news coverage?

News coverage about NCNA stock has trended negative this week, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. NuCana earned a news sentiment score of -2.3 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for NuCana.

Who are some of NuCana's key competitors?

What other stocks do shareholders of NuCana own?

Who are NuCana's key executives?

NuCana's management team includes the folowing people:
  • Prof. Christopher B. Wood, Chairman & Chief Medical Officer (Age 73)
  • Mr. Hugh S. Griffith, Founder, CEO & Director (Age 51)
  • Mr. Donald Munoz, Chief Financial Officer (Age 50)

When did NuCana IPO?

(NCNA) raised $100 million in an IPO on Thursday, September 28th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Citigroup, Jefferies and Cowen acted as the underwriters for the IPO and William Blair was co-manager.

Who are NuCana's major shareholders?

NuCana's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (1.89%), UBS Asset Management Americas Inc. (0.57%), Asymmetry Capital Management L.P. (0.50%), Marshall Wace North America L.P. (0.11%), Alps Advisors Inc. (0.10%) and Rothschild Investment Corp IL (0.09%).

Which institutional investors are selling NuCana stock?

NCNA stock was sold by a variety of institutional investors in the last quarter, including Alps Advisors Inc., Marshall Wace North America L.P. and UBS Asset Management Americas Inc..

Which institutional investors are buying NuCana stock?

NCNA stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Asymmetry Capital Management L.P., Rothschild Investment Corp IL, Susquehanna International Group LLP, Aperio Group LLC and Tower Research Capital LLC TRC .

How do I buy shares of NuCana?

Shares of NCNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NuCana's stock price today?

One share of NCNA stock can currently be purchased for approximately $6.95.

How big of a company is NuCana?

NuCana has a market capitalization of $224.00 million. The company earns $-18,470,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis. NuCana employs 21 workers across the globe.View Additional Information About NuCana.

What is NuCana's official website?

The official website for NuCana is

How can I contact NuCana?

NuCana's mailing address is 3 LOCHSIDE WAY, EDINBURGH X0, EH12 9DT. The company can be reached via phone at 44-0-13-1357-1111 or via email at chris.[email protected]

MarketBeat Community Rating for NuCana (NASDAQ NCNA)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  177 (Vote Outperform)
Underperform Votes:  157 (Vote Underperform)
Total Votes:  334
MarketBeat's community ratings are surveys of what our community members think about NuCana and other stocks. Vote "Outperform" if you believe NCNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NCNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/17/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel